This past fall, the National Institutes of Health, the Food and Drug Administration and other partners launched the Bespoke Gene Therapy Consortium in an effort to leverage adeno-associated viruses as vectors to treat rare diseases. The initiative seeks to streamline research to clinical use, driving efficiencies into the traditional research and development process. FDA leader Peter Marks and NIH’s P.J. Brooks discuss the consortium’s work and how it aims to help people with rare diseases.
HealthCast
Season 2
Episode 39
21m listen
Gene Therapy is Fighting Rare Diseases in FDA, NIH Program
Share
The technique aims to treat some diseases by gene replacement.
-
Dr. Peter Marks Director CBER, FDA -
Deputy Director, Office of Rare Diseases Research NCATS, NIH
Related Content
-
NOAA Improves Geospatial Accuracy With NSRS Modernization
NOAA is integrating GPS and new gravity data to improve accuracy of its National Spatial Reference System.
9m listen -
How to Help Tech Cross the Valley of Death
Leslie Beavers discussed down how her firm, LB Insights, guides firms toward delivering capabilities aligned with DOW modernization goals.
10m watch -
Humanizing Cybersecurity Through a ‘Safer Shift’
Cybersecurity isn’t just tech. Safer Shift’s Tiziana Barrow shares how storytelling can make digital safety intuitive and human.
24m watch -
Staying Ahead of AI-Driven Cyber Threats
Robert Roser shares insights on emerging cybercrime trends, supply chain risks and how federal organizations can build stronger security through zero trust.
8m watch